Goldenwell Biotech, Inc.
GWLL
$0.70
-$0.07-9.09%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -37.40K | 100.00 | 100.00 | 62.30K | 37.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.40K | 100.00 | 100.00 | 62.30K | 37.30K |
| Cost of Revenue | 174.80K | 174.80K | 174.80K | -100.00 | -100.00 |
| Gross Profit | -212.20K | -212.20K | -212.20K | 24.90K | -100.00 |
| SG&A Expenses | 106.60K | 100.00K | 105.10K | 118.80K | 108.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 281.30K | 274.70K | 279.80K | 118.70K | 108.80K |
| Operating Income | -318.80K | -312.20K | -317.30K | -93.80K | -108.90K |
| Income Before Tax | -311.40K | -304.80K | -325.70K | -104.30K | -119.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.31 | -0.30 | -0.33 | -0.10 | -0.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.40K | -304.80K | -325.70K | -104.30K | -119.40K |
| EBIT | -318.80K | -312.20K | -317.30K | -93.80K | -108.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 401.13M | 401.13M | 401.13M | 401.13M | 401.13M |
| Average Diluted Shares Outstanding | 401.13M | 401.13M | 401.13M | 401.13M | 401.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |